DossierENTITY

BTK degrader

Coverage of BTK degrader in the Nexus archive.

Earliest in view: Jun 8 · 13:20 UTCMost recent: Jun 8 · 13:20 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 8 · 13:20 UTCQUARTZ
Roche is striking a $2.3 billion deal with Nurix Therapeutics to develop a blood cancer drug
Roche is entering a $2.3 billion deal with Nurix Therapeutics to develop bexobrutideg, an oral BTK degrader. Nurix receives $700 million upfront for co-developing the drug targeting chronic lymphocytic leukemia and other diseases.